The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis
Open accessAbstract
UNLABELLED The literature on metastasis-directed therapy for oligometastatic prostate cancer (PCa) recurrence consists of small heterogeneous studies. This study aimed to reduce the heterogeneity by pooling individual patient data from different institutions treating oligometastatic PCa recurrence with stereotactic body radiotherapy (SBRT). We focussed on patients who were treatment naive, with the aim of determining if SBRT could delay disease progression. We included patients with three or fewer metastases. The Kaplan-Meier method was used to estimate distant progression-free survival (DPFS) and local progression-free survival (LPFS). Toxicity was scored using the Common Terminology Criteria for Adverse Events. In total, 163 metastases were treated in 119 patients. The median DPFS was 21 mo (95% confidence interval, 15-26 mo). A lower radiotherapy dose predicted a higher local recurrence rate with a 3-yr LPFS of 79% for patients treated with a biologically effective dose ≤100Gy versus 99% for patients treated with >100Gy (p=0.01). Seventeen patients (14%) developed toxicity classified as grade 1, and three patients (3%) developed grade 2 toxicity. No grade ≥3 toxicity occurred. These results should serve as a benchmark for future prospective trials. PATIENT SUMMARY This multi-institutional study pools all of the available data on the use of stereotactic body radiotherapy for limited prostate cancer metastases. We concluded that this approach is safe and associated with a prolonged treatment progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Potters, L., Kavanagh, B., Galvin, J. M., Hevezi, J. M., Janjan, N. A., Larson, D. A., Mehta, M. P., Ryu, S., Steinberg, M., Timmerman, R., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.042 · Cited by 664
21 years of Biologically Effective Dose
Fowler, J. F. (2010) · The British Journal of Radiology · doi:10.1259/bjr/31372149 · Cited by 639
Stereotactic body radiotherapy for oligometastases
Tree, A. C., Khoo, V. S., Eeles, R. A., Ahmed, M., Dearnaley, D. P., Hawkins, M. A., Huddart, R. A., Nutting, C. M., Ostler, P. J., & van As, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70510-7 · Cited by 524
Self-citationOst, P., Bossi, A., Decaestecker, K., De Meerleer, G., Giannarini, G., Karnes, R. J., Roach, M., & Briganti, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.004 · Cited by 349
Self-citationRepeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Decaestecker, K., De Meerleer, G., Lambert, B., Delrue, L., Fonteyne, V., Claeys, T., De Vos, F., Huysse, W., Hautekiet, A., Maes, G., et al. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-135 · Cited by 255
Self-citationSuardi, N., Gandaglia, G., Gallina, A., Di Trapani, E., Scattoni, V., Vizziello, D., Cucchiara, V., Bertini, R., Colombo, R., Picchio, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.02.011 · Cited by 230
Jereczek-Fossa, B. A., Beltramo, G., Fariselli, L., Fodor, C., Santoro, L., Vavassori, A., Zerini, D., Gherardi, F., Ascione, C., Bossi-Zanetti, I., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.031 · Cited by 228
Self-citationSchick, U., Jorcano, S., Nouet, P., Rouzaud, M., Vees, H., Zilli, T., Ratib, O. M., Weber, D. C., & Miralbell, R. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.764010 · Cited by 156
Self-citationStereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
Ahmed, K. A., Barney, B. M., Davis, B. J., Park, S. S., Kwon, E. D., & Olivier, K. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2012.00215 · Cited by 141
Self-citation
Cited by
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Self-citationTreatment of Advanced Prostate Cancer
Teo, M. Y., Rathkopf, D. E., & Kantoff, P. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-051517-011947 · Cited by 726
Lievens, Y., Guckenberger, M., Gomez, D., Hoyer, M., Iyengar, P., Kindts, I., Méndez Romero, A., Nevens, D., Palma, D., Park, C., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.04.003 · Cited by 672
Han, S., Woo, S., Kim, Y. J., & Suh, C. H. (2018) · European Urology · doi:10.1016/j.eururo.2018.03.030 · Cited by 331
Siva, S., Bressel, M., Murphy, D. G., Shaw, M., Chander, S., Violet, J., Tai, K. H., Udovicich, C., Lim, A., Selbie, L., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.004 · Cited by 322
Metadata
- Authors
- Ost, P., Jereczek-Fossa, B. A., As, N. V., Zilli, T., Muacevic, A., Olivier, K., Henderson, D., Casamassima, F., Orecchia, R., Surgo, A., Brown, L., Tree, A., Miralbell, R., & De Meerleer, G.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 69
- Issue
- 1
- Pages
- 9-12
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2148867458
- Cited by
- 290
- References
- 13
- FWCI
- 28.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. https://app.cochat.ai/papers/10.1016/j.eururo.2015.07.004
- The paper
- Ost, P., Jereczek-Fossa, B. A., As, N. V., Zilli, T., Muacevic, A., Olivier, K., Henderson, D., Casamassima, F., Orecchia, R., Surgo, A., Brown, L., Tree, A., Miralbell, R., & De Meerleer, G. (2016). Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. European Urology. https://doi.org/10.1016/j.eururo.2015.07.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.